DUBLIN--(BUSINESS WIRE)--Jan 14, 2020--

Market Outlook

This research has estimated the growth of the drug discovery market in the Middle East and Africa at a CAGR of 7.48% during the forecasted period 2019-2027.

The UAE, Turkey, Saudi Arabia, South Africa, and the Rest of Middle East & Africa constitute the market for drug discovery in the Middle East and Africa region.

There is an increase in the adoption of HTS (high throughput screening) technology in the Middle East and Africa region for various drug development processes. The technology is used in lead identification to discover an inhibitor for the Middle East respiratory syndrome (MERS). The rising prevalence of diseases like AIDS, Alzheimer's, and other drug-resistant infectious diseases, has also resulted in the discovery of new bioactive compounds. These factors have been driving the drug discovery market significantly.

South Africa has started focusing on developing novel drugs for evolving diseases. Due to the increase in acute and chronic diseases, the demand for small molecule therapeutics is growing in the country. The Council for Scientific and Industrial Research (CSIR) biosciences unit is conducting a large collaborative malaria research project with the help of HTS technology. The project is being funded by several public-private foundations and more than 50 scientists are contributing to the research project across several South African universities and research institutions.

The country is also dedicated to the establishment of necessary initiatives and infrastructure that could aid in the development of the pharmaceutical value chain, which includes HTS, medicinal chemistry, and preclinical testing facilities. This is said to result in increased drug discovery procedures, rising partnerships among companies, and government organizations in the country to implement the process, and hence, create ample opportunities for the growth of the drug discovery market.

Key Topics Covered:

1. Middle East and Africa Drug Discovery Market - Summary

2. Industry Outlook

2.1. Market Definition

2.2. Porter's Five Forces Model

2.2.1. Threats of New Entrants

2.2.2. Threat of Substitute Products

2.2.3. Bargaining Power of Buyers

2.2.4. Bargaining Power of Suppliers

2.2.5. Competitive Rivalry

2.3. Pestle Outlook

2.4. Value Chain Outlook

2.5. Market Attractiveness Index

2.6. Key Insight

2.7. Market Drivers

2.7.1. Growing Aged Population

2.7.2. Technological Advancements

2.7.3. Rise in the Healthcare Expenditure

2.7.4. Surge in Lifestyle-Oriented Diseases

2.8. Market Restraints

2.8.1. Delay in Product Launches

2.8.2. Restricting Growth Rate of A Drug Due to Generic Drugs

2.9. Market Opportunities

2.9.1. Significant Investment By Healthcare Industries in Improving Big-Data Analytical Capabilities

2.9.2. Rising Demand for Specialty Medicines

2.10. Market Challenges

2.10.1. Stringent Government Regulations

3. Drug Discovery Market Outlook - By Drug Type

3.1. Small Molecule Drug

3.2. Biologic Drug

4. Drug Discovery Market Outlook - By Technology

4.1. High Throughput Screening

4.2. Biochips

4.3. Bioinformatics

4.4. Pharmacogenomics and Pharmacogenetics

4.5. Combinatorial Chemistry

4.6. Nanotechnology

4.7. Spectroscopy

4.8. Metabolomics

4.9. Other Technologies

5. Drug Discovery Market Outlook - By Service

5.1. Drug Metabolism and Pharmacokinetics (Dmpk) Services

5.2. Chemical Services

5.3. Biological Services

5.4. Other Pharmaceutical Services

6. Drug Discovery Market Outlook - By End-User

6.1. Research Institutes

6.2. Pharmaceutical Companies

6.3. Contract Research Organizations (Cros)

6.4. Other End-Users

7. Drug Discovery Market - Regional Outlook

7.1. Middle East and Africa

7.1.1. Country Analysis

7.1.1.1. Saudi Arabia

7.1.1.2. Turkey

7.1.1.3. United Arab Emirates

7.1.1.4. South Africa

7.1.1.5. Rest of Middle East & Africa

8. Company Profiles

8.1. 3M Company

8.2. Abbott Laboratories Inc.

8.3. Agilent Technologies, Inc.

8.4. Antares Pharma

8.5. Astrazeneca Plc

8.6. Bayer Ag

8.7. Becton, Dickinson and Company (Bd)

8.8. Boehringer Ingelheim

8.9. Eli Lily and Company

8.10. F. Hoffmann-La Roche Ltd.

8.11. Glaxosmithkline Llc

8.12. Johnson & Johnson

8.13. Merck & Co., Inc.

8.14. Novartis

8.15. Pfizer, Inc.

8.16. Sanofi

9. Research Methodology & Scope

9.1. Research Scope & Deliverables

9.1.1. Objectives of Study

9.1.2. Scope of Study

9.2. Sources of Data

9.2.1. Primary Data Sources

9.2.2. Secondary Data Sources

9.3. Research Methodology

9.3.1. Evaluation of Proposed Market

9.3.2. Identification of Data Sources

9.3.3. Assessment of Market Determinants

9.3.4. Data Collection

9.3.5. Data Validation & Analysis

For more information about this report visit https://www.researchandmarkets.com/r/xt9ye5

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD: MIDDLE EAST AFRICA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/14/2020 07:16 AM/DISC: 01/14/2020 07:16 AM

Copyright Business Wire 2020.